Etretinate
Systematic (IUPAC) name
ethyl 9-(4-methoxy-2,3,6-trimethyl-phenyl)- 3,7-dimethyl-nona- 2,4,6,8-tetraenoate
Identifiers
CAS number	54350-48-0
ATC code	D05BB01
PubChem	3312
DrugBank	APRD00966
Chemical data
Formula	C23H30O3
Mol. mass	354.483 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	120 days
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral

Etretinate (trade name Tigason) is a medication used to treat severe psoriasis. It was removed from the United States market in 1998 and the Canadian market in 1996, due to the high risk of birth defects.

Etretinate has been replaced by acitretin, a metabolite of etretinate.

[edit] Precautions

• Etretinate is a teratogen, and may cause birth defects long after use. Therefore, etretinate should only be used if one is never to get pregnant.
• Etretinate should be avoided in children, as it may interfere with growth of bone.

[edit] Side effects

• Hepatitis
• Pseudotumor cerebri

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.